News

Stuart Therapeutics Welcomes New Board Members for Growth

Stuart Therapeutics Welcomes New Board Members for Growth

Stuart Therapeutics Welcomes New Board Members

Stuart Therapeutics is excited to announce the addition of two prominent leaders in the field of ophthalmology, enhancing their Board of Directors as they move towards significant developments in therapeutics.

New Appointees Bring Vast Experience

Tracy Valorie and Jason Werner have been appointed to the Board, increasing the total board membership to five. This strategic move follows the passing of Robert O. Baratta, MD, and the recent resignation of retired US Representative Diane Black, RN.

Tracy Valorie's Background

Tracy Valorie is a well-respected figure in the pharmaceutical and biotech industry, serving as a strategic business consultant and owner of TMV Associates LLC since 2019. With over 30 years of dedicated experience, she held the position of Senior Vice President at Bausch + Lomb, where she was pivotal in managing the U.S. pharmaceutical divisions. Prior to that, Tracy led the ophthalmology sector at Pfizer, showcasing her ability to drive growth and innovation in the industry. Her extensive network and expertise in commercial development will be invaluable as Stuart Therapeutics navigates its next phases of growth.

Jason Werner's Experience

Executively leading Sightstream Biotherapeutics, Jason Werner brings a wealth of expertise in regenerative ophthalmic therapies. His track record includes playing crucial roles at Eyevance Pharmaceuticals and Alimera, where his leadership guided the company through transformative sales and development in the highly competitive biotech arena. With a degree in business administration, Jason's insights into commercial strategies will significantly benefit Stuart Therapeutics as they aim to broaden their therapeutic offerings.

Strategic Transition for Growth

Expressing his enthusiasm, Eric Schlumpf, President and CEO of Stuart Therapeutics, stated, "The addition of Tracy and Jason to our Board signifies a pivotal moment for our company. Their combined experiences will be critical as we transition into an exciting phase of growth and development in ophthalmology therapeutics. We also acknowledge the significant contributions made by Bob Baratta and Diane Black in shaping our organization during its formative years."

Vision for Future Impact

Tracy Valorie voiced her excitement about joining the board, highlighting her eagerness to contribute to innovative treatments that aim to make a lasting impact on patients with ophthalmic disorders. She is committed to leveraging her experience to ensure successful collaborations that will propel the company's achievements in the sector.

Jason Werner added, "This is a pivotal time for Stuart Therapeutics. With anticipated milestone developments on the horizon, I am eager to work closely with Tracy and Eric to ensure that our pipeline offerings successfully reach patients while maximizing shareholder value for Stuart and its investors."

About Stuart Therapeutics, Inc.

Stuart Therapeutics, Inc. is a dynamic, clinical-stage entity focusing on ophthalmic therapies. Their flagship asset, ST-100, is nearing completion of its Phase 3 trial, with expectations set for a readout early next year. Additionally, the company is advancing innovative programs targeting retinal diseases and myopia, coupled with a collaboration for neuroprotection in glaucoma through a partnership with Glaukos Corp.

Frequently Asked Questions

Who are the new board members at Stuart Therapeutics?

The new board members are Tracy Valorie and Jason Werner, both experienced leaders in ophthalmology and biotechnology.

What is the primary focus of Stuart Therapeutics?

Stuart Therapeutics specializes in developing clinical-stage therapies for ophthalmic conditions, focusing on innovative solutions for eye diseases.

Why did previous board members step down?

Robert O. Baratta passed away, and Diane Black recently resigned. Their contributions were significant during the company's early stages.

What qualifications do Tracy Valorie and Jason Werner bring?

Valorie has extensive experience in pharmaceutical management, and Werner has a strong background in biotech operations, both crucial for guiding Stuart's future.

What are the next steps for Stuart Therapeutics following this announcement?

The focus will be on progressing their lead asset ST-100 through clinical trials and enhancing their therapeutic offerings in ophthalmology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

XPLR Infrastructure Faces Class Action Lawsuit Outcry

Updated Category News Views 170

Class Action Lawsuit Filed Against XPLR Infrastructure Levi & Korsinsky, LLP has announced a class action lawsuit concerning XPLR Infrastructure, LP, previously known as Nextera Energy Partners, LP. This lawsuit addresses significant concerns regarding securities fraud that impacted numerous investors, particularly those who held shares during the specified time frame....

Continue Reading
PharmAla Reports Impressive Growth and Key Milestones Achieved

Updated Category News Views 291

PharmAla Biotech Holdings Shareholder Update PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has recently shared their financial and operational performance metrics providing insight into their notable achievements up to the end of May 2025. Focusing on the development and distribution of LaNeo™ MDMA, along with other novel...

Continue Reading
Discover the Bold New Batch of Sagamore Spirit Rye Whiskey

Updated Category News Views 387

Discover the Bold New Batch of Sagamore Spirit Rye Whiskey The 100% Maryland-made whiskey is 7-Years-Old and 123 Proof Sagamore Spirit, the celebrated Maryland rye distillery, is introducing a new batch of their award-winning Cask Strength Rye Whiskey. This exceptional spirit boasts a seven-year age profile and carries a robust ABV of 61.5%. The whiskey delights the...

Continue Reading
Stocks to Eye: Ciena, Oracle, and Other Market Movers Ahead

Updated Category News Views 166

Market Trends to Watch This Thursday As U.S. stock futures experience a downward shift, investors are keenly eyeing some significant stocks that could impact market movements today. Among them, several prominent companies are set to announce their earnings, potentially affecting their stock performance and overall market sentiment. Ciena Corp. on Investor's Radar Wall...

Continue Reading
The Perfect Franchise Conference Boosts Industry Engagement

Updated Category News Views 144

The Perfect Franchise Annual Conference: A Catalyst for Growth The Perfect Franchise (TPF), a leader in the realm of franchise consulting and coaching, has seen notable advancements, particularly in the wake of their annual conference. As the franchise industry blooms, this gathering serves not just as an event but as a beacon of growth for both franchise brands and...

Continue Reading